Serum Rifampicin Levels in Patients with Tuberculosis: Effect of P-Glycoprotein and CYP3A4 Blockers on its Absorption
Authors: Prakash J.1; Velpandian T.1; Pande J.N.2; Gupta S.K.1
Source: Clinical Drug Investigation, Volume 23, Number 7, 2003 , pp. 463-472(10)
Publisher: Adis International
Abstract:
Objective: To identify patients with tuberculosis (TB) showing poor bioavailability for rifampicin and to delineate the role of possible factors such as overexpression of intestinal cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (PGP) in the drugs bioavailability by administering known blockers.Patients, design and setting: 77 clinically proven TB patients were included in this nonblinded, randomised, comparative trial carried out at one centre at the All India Institute of Medical Sciences, New Delhi, India.Interventions: The concentrations of rifampicin and its active metabolite, 25-desacetylrifampicin (DRMP), were measured in blood samples of the 77 TB patients at 0, 1, 2 and 4 hours after their usual morning rifampicin dose. Of these, 19 patients showing the lowest area under the concentration-time curve values from 0 to 4 hours after administration (AUC0-4) were selected and pretreated with a single dose of either verapamil (80mg) or itraconazole (200mg) as both PGP and CYP3A4 blockers 1 hour prior to rifampicin administration. Rifampicin and DRMP concentrations were estimated using high performance liquid chromatography in all serum samples collected at the same timepoints.Main outcome measures and results: A statistically significant increase (p < 0.05) was found both in the serum levels of rifampicin at 2 hours and in the AUC0-4 values (158% and 84%, respectively) after pretreatment with verapamil. However, an increase in the levels of rifampicin was found to be insignificant on pretreatment with itraconazole. The estimated levels of DRMP also supported these results.Conclusions: The increase in rifampicin levels on administration of a PGP/CYP3A4 blocker suggests a pivotal role for PGP/CYP3A4 in the absorption of rifampicin in patients with TB, which may be responsible for lower or variable levels of rifampicin.Keywords: Rifampicin, pharmacokinetics; Antibacterials, pharmacokinetics
Document Type: Research article
Affiliations: 1: 1 Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India 2: 2 Department of Medicine, All India Institute of Medical Sciences, New Delhi, India

Click here for Page Help